BIOGEN IDEC LIMITED

Their core work

Biogen is a major global biopharmaceutical company specializing in neurological and neurodegenerative diseases, with strong focus areas in multiple sclerosis and Alzheimer's disease. In H2020 projects, they contribute industry expertise in digital health monitoring, real-world evidence generation, and patient outcome measurement. Their participation centers on developing and validating digital tools — wearables, smartphones, and remote assessment technologies — to better track disease progression and treatment efficacy in conditions like MS, Alzheimer's, and immune-mediated inflammatory disorders.

What they specialise in

How they've shifted over time

Early H2020 work (2016–2018) focused on building digital monitoring infrastructure — wearable devices, smartphones, experience sampling, and speech analysis for CNS conditions like multiple sclerosis, depression, and epilepsy. By 2019, the focus shifted toward measurable clinical outcomes: digital endpoints, real-world evidence, health economics, and quality-of-life metrics in neurodegenerative and immune-mediated diseases. This reflects a maturation from "can we collect digital data?" to "can we use digital data to prove treatment value?"

Biogen is moving toward validated digital biomarkers and health-economic evidence for neurodegenerative therapies, making them a strong partner for projects needing pharma-grade digital endpoint development.

How they like to work

Biogen participates exclusively as a consortium partner, never coordinating — typical for large pharma companies contributing industry perspective and clinical expertise to academic-led initiatives. With 111 unique partners across 19 countries, they operate in large, multi-stakeholder consortia (often IMI-funded public-private partnerships). This means they are experienced collaborators who bring industry data, patient access, and regulatory insight, but expect others to handle project management.

Biogen has built a broad European network of 111 unique partners across 19 countries, largely through large IMI-style consortia. Their reach is pan-European with likely connections to major academic medical centers, other pharma companies, and digital health SMEs working on neurological conditions.

What sets them apart

Biogen brings something rare to H2020 consortia: a major pharma company's perspective on what digital health tools need to look like to actually change clinical practice and regulatory decisions. Their consistent focus on neurological diseases across all four projects means they offer deep domain knowledge, not shallow involvement. For consortium builders, Biogen adds commercial credibility, potential routes to market for digital health innovations, and access to real-world patient data at scale.

Highlights from their portfolio

• RADAR-CNS
  Flagship project (2016–2022) developing remote assessment using wearables and smartphones across three major CNS disorders — MS, depression, and epilepsy — setting a foundation for digital biomarkers.
• IDEA-FAST
  Long-running project (2019–2026) specifically focused on identifying validated digital endpoints for fatigue and sleep in neurodegenerative and inflammatory diseases, representing the next generation of digital health evidence.
• ROADMAP
  Built a multimodal data access platform for real-world Alzheimer's outcomes and health economics — directly connecting research data to care improvement and reimbursement decisions.